Premium
An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high‐throughput method
Author(s) -
Yin Yingxian,
Xu Yi,
Ou Zhiying,
Yang Xiangling,
Liu Huanliang
Publication year - 2019
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25463
Subject(s) - cytopathic effect , virology , virus quantification , enterovirus , ribavirin , titer , antiviral drug , high throughput screening , drug , biology , nat , virus , pharmacology , hepatitis c virus , bioinformatics , computer network , computer science
Plaque assay plays an irreplaceable role in a variety of virological studies, including determining titers of viruses. Our previous study showed that a simple and highly repeatable plaque assay could be used for enterovirus 71 (EV‐A71). Now, we show that using a subclone of a clinical EV‐A71 isolate and a rhabdomyosarcoma cell line (RD), a plaque assay based on an EV‐A71/RD model could exhibit the most rapid formation of plaques (<2 days), with much higher repeatability and consistency. Inspired by a plaque inhibitory test for testing ribavirin and interferon, as well as a plaque reduction neutralization test, this modified method has been used to establish a convenient system by using 96‐well plates for screening anti‐EV‐A71 drugs from a 130‐compound library containing multiple types of inhibitors. Nine candidate effective compounds for EV‐A71 have been screened out, and among them, nobiletin ( flavonoid ) was found to be a novel effective compound at the concentration of 10 μM. Our findings imply that this improved method based on an EV‐A71/RD model proved to be a potential high‐throughput method in screening novel antiviral drugs for EV‐A71. Undoubtedly, this method can also be applied to other viruses that can produce an obvious cytopathic effect.